- Home
- SPCE vs EDIT Comparison
SPCE vs EDIT Comparison
Compare SPCE & EDIT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SPCE | EDIT |
|---|---|---|
| Founded | 2017 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Transportation Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 207.3M | 206.0M |
| IPO Year | 2017 | 2016 |
Fundamental Metrics
Financial Performance| Metric | SPCE | EDIT |
|---|---|---|
| Price | $2.50 | $2.44 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 5 | 6 |
| Target Price | $3.86 | ★ $4.92 |
| AVG Volume (30 Days) | 1.5M | ★ 1.7M |
| Earning Date | 01-01-0001 | 06-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 37.50 |
| EPS | N/A | ★ N/A |
| Revenue | $7,036,000.00 | ★ $31,937,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $2,528.09 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | 3.47 | ★ 132.64 |
| 52 Week Low | $2.18 | $0.91 |
| 52 Week High | $5.59 | $4.54 |
Technical Indicators
Market Signals| Indicator | SPCE | EDIT |
|---|---|---|
| Relative Strength Index (RSI) | 39.29 | 58.88 |
| Support Level | $2.37 | $2.42 |
| Resistance Level | $2.67 | $2.76 |
| Average True Range (ATR) | 0.11 | 0.20 |
| MACD | 0.01 | 0.06 |
| Stochastic Oscillator | 17.31 | 65.08 |
Price Performance
Historical ComparisonAbout SPCE Virgin Galactic Holdings Inc.
Virgin Galactic Holdings Inc is a United States-based vertically integrated aerospace company pioneering human spaceflight for private individuals & researchers, and it also manufactures air and space vehicles. Using technologies, the company is developing a spaceflight system designed to offer its customers a multi-day, and transformative experience. This culminates in a spaceflight that includes views of Earth from space and several minutes of weightlessness that will launch from Spaceport America, New Mexico.
About EDIT Editas Medicine Inc.
Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR)/ CRISPR-associated protein 9 (Cas9 technology). It has developed CRISPR/Cas9 technology which uses a protein-RNA (ribonucleic acid) complex composed of the Cas9 enzyme bound to a guide RNA molecule designed to recognize a DNA (deoxyribonucleic acid) sequence that requires repair. The company is engaged in developing and commercializing genome editing technology.